Previous 10 | Next 10 |
Thinly traded nano cap AzurRx BioPharma (AZRX) perks up 9% premarket on light volume in reaction to the commencement of dosing in Turkey in an open-label Phase 2 clinical trial evaluating MS1819, combined with standard-of-care [porcine -derived pancreatic enzyme replacement therapy ...
Patient screening and dosing ongoing in Turkey and Hungary Topline data expected in Q2 2021 for the Combination Trial DELRAY BEACH, Fla., Nov. 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a c...
LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episod...
Potential to add additional study arm utilizing immediate release capsules Trial objectives, endpoints and statistical analysis to remain the same DELRAY BEACH, Fla., Nov. 17, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or ...
DELRAY BEACH, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that ...
NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- via InvestorWire -- AzurRx BioPharma, Inc. ( NASDAQ: AZRX ) (“AzurRx” or the “Company”), a New York-based biopharmaceutical company specializing in the development of therapeutic proteins for...
Globally recognized experts in cystic fibrosis and chronic pancreatitis care and research to support AzurRx in advancing the clinical development of MS1819 NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “...
AzurRx BioPharma ([[AZRX]]) has activated two trial sites in Turkey for its Phase 2 trial, evaluating MS1819 combined with porcine pancreatic enzyme replacement therapy ((PERT)), in cystic fibrosis ((CF)) patients with severe exocrine pancreatic insufficiency ((EPI))....
Two clinical trial sites activated in Turkey, with patient screening initiated Follows activation of six clinical sites in Hungary and dosing of first eight patients Topline data expected in Q2 2021 NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE)...
Abstracts to Focus on: Results from Phase 2, Open-Label, Multicenter, 2x2 Cross-Over Trial to Assess Safety and Efficacy of MS1819 in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis & Best Enteric Capsule for Targeted Duodenal Delivery of Non-Porcine ...
News, Short Squeeze, Breakout and More Instantly...
AzurRx BioPharma Inc. Company Name:
AZRX Stock Symbol:
NASDAQ Market:
AzurRx BioPharma Inc. Website:
BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (G...
Why Investors Are Watching These 3 Penny Stocks Right Now There are plenty of ways to find the best penny stocks to buy right now. And, one method that many penny stocks investors use is looking at what top investors are buying alongside other metrics. While this can be a good strat...
BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastroint...